| Literature DB >> 29204285 |
I M S Al-Kadmy1, A N M Ali1, I M A Salman1, S S Khazaal1.
Abstract
Healthcare-associated items are a common source of acquired infections, and hospital-acquired infections cause significant mortality and morbidity worldwide. Acinetobacter baumannii is the most prevalent infection-causing organism in the hospital environment. Hospital articles and objects are the main sources of infection with the ability to transmit some of the pathogenic microorganisms such as A. baumannii, which is considered a serious problem in therapeutic treatments. In the current study, we isolated A. baumannii from hospital sources and evaluated its antibiotic resistance, virulence factors and resistance gene determinants. The isolates were identified phenotypically as well as genotypically using PCR. In addition, their capability for biofilm formation and ten other virulence factors were measured. Of 112 samples, 21 showed growth of the target organism. Apart from A. baumannii, isolates of Candida albicans, Staphylococcus sp., Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae were also grown. Antibiotic susceptibility test results considered all the A. baumannii to be multidrug-resistant isolates with the highest resistance being 100% to gentamycin, ciprofloxacin; the most effective antibiotics with 100% susceptibility was colistin and tigecycline. All A. baumannii isolates had MIC for ceftriaxone >32 mg/L. All A. baumannii isolates from the hospital environment showed multidrug resistance and had many virulence factors. They have long-term resistance to dry conditions and cause a serious public health issue.Entities:
Keywords: Acinetobacter baumannii; biofilm; hospital environments; multidrug-resistant biofilm
Year: 2017 PMID: 29204285 PMCID: PMC5705800 DOI: 10.1016/j.nmni.2017.10.010
Source DB: PubMed Journal: New Microbes New Infect ISSN: 2052-2975
Primers details used in this study
| Primer name | Primer sequence | Base length | References |
|---|---|---|---|
| CTX-M1C-f | GACTATTCATGTTGTTGTTATTTC | 923 | |
| CTX-M1C-R | TTACAAACCGTTGGTGACG | ||
| preOXA-48-f | TATATTGCATTAAGCAAGGG | 800 | |
| preOXA-48-r | CACACAAATACGCGCTAACC | ||
| VIM2-f | GATGGTGTTTGGTCGCATA | 390 | |
| VIM2-r | CGAATGCGCAGCACCAG | ||
| SHV-1 | CGCCGGGTTATTCTTATTTGTCGC | 1016 | |
| SHV-2 | TCTTTCCGATGCCGCCGCCAGTCA | ||
| CTX-M2A | ACTCAGAGCATTCGCCGCTCA | 879 | |
| CTX-M2B | TTATTGCATCAGAAACCGTG | ||
| CTX-M9A | ATGGTGACAAAGAGAGTGCAACG | 837 | |
| CTX-M9B | ACAGCCCTTCGGCGATGATTC | ||
| IMP2-f | GGAATAGAGTGGCTTAAYTCTC | 232 | |
| IMP2-r | CCAAACYACTASGTTATCT | ||
| TEM-1 | ATAAAATTCTTGAAGAC | 1079 | |
| TEM-2 | TTACCAATGCTTAATCA | ||
| preNDM-f | CACCTCATGTTTGAATTCGCC | 984 | |
| preNDM-r | CTCTGTCACATCGAAATCGC | ||
| Bla KPC | ATGTCACTGTATCGCCGTCT | 882 | |
| Bla KPC | TTACTGCCCGTTGACGCCC | ||
| AAGATGGAGTTTCCTATGCAGGAG | 498 | ||
| CATTCAGAGTCCTGCCCTCATTATT | |||
| ACTCTGACTTGACTATTACC | 200 | ||
| AGATGCAGTCTGGTCAAC | |||
| CACACACAAACGGGAGCTGTT | 680 | ||
| CTTCCCGCAGCATAGTTCCAT | |||
| GGCTGGACATCATGGGAACTGG | 300 | ||
| CGTCGGGAACGGGTAGAATCG |
Antibiotic susceptibility profile of study isolates
| Sample ID | Organism | Antibiotic susceptibility profile | Ceftriaxone MIC (E-test) | PCR results (ESBL) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gen | Tb | Cef | Cet | Imp | MRP | Cip | Lev | Tet | Sxt | Col | PB | TG | Amp/sul | ||||
| 1 | S | S | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 2 | R | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM | |
| 3 | R | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM | |
| 4 | R | R | R | R | R | R | R | R | R | R | S | R | S | R | >32 mg/L | TEM, SHV, IMP | |
| 5 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | TEM, SHV | |
| 6 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 7 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | TEM | |
| 8 | S | R | R | R | S | S | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 9 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM | |
| 10 | S | R | S | R | S | S | R | R | R | R | S | S | S | R | >32 mg/L | NEG | |
| 11 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 12 | S | R | S | S | S | S | R | R | S | R | S | S | S | S | >32 mg/L | NEG | |
| 13 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 14 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 15 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 16 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, SHV | |
| 17 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 18 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 19 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 20 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| 21 | S | R | R | R | R | R | R | R | R | R | S | S | S | R | >32 mg/L | CTXM, TEM | |
| Susceptible | 18 | 1 | 2 | 1 | 3 | 3 | 0 | 0 | 1 | 0 | 21 | 20 | 21 | 1 | |||
| Resistant | 3 | 20 | 19 | 20 | 18 | 18 | 21 | 21 | 20 | 21 | 0 | 1 | 0 | 20 | |||
Abbreviations: Amp/sul, ampicillin/sulbactam; Cef, cefepime; Cet, ceftriaxone; Cip, ciprofloxacin; Col, colistin; Gen, gentamicin; Imp, imipenem; Lev, levofloxacin; MRP, meropenem; Sxt, trimethoprim/sulfamethoxazole; PB, polmyxin B; TB, tobramycin; Tet, tetracycline; TG, tigecycline.
Fig. 1Antibiotic susceptibility profile for study isolates.
Antibiotic susceptibility profile of study isolates with MIC50 and MIC90 value
| Antibiotic family | Antibiotic | Breakpoints | MIC50 (mg/L) | MIC90 (mg/L) | Resistant (%) | Susceptible (%) | ||
|---|---|---|---|---|---|---|---|---|
| S | I | R | ||||||
| Aminoglycosides | Gentamicin | ≤4 | 8 | ≥16 | 4 | 8 | 14.3 | 85.7 |
| Tobramycin | ≤4 | 8 | ≥16 | 16 | 32 | 95.2 | 4.8 | |
| Cephalosporins | Cefepime | ≤8 | 16 | ≥32 | 16 | 32 | 90.5 | 9.5 |
| Ceftriaxone | ≤8 | 16–32 | ≥64 | 16 | 32 | 95.2 | 4.8 | |
| Carbapenems | Imipenem | ≤2 | 4 | ≥8 | 8 | 16 | 85.7 | 14.3 |
| Meropenem | ≤2 | 4 | ≥8 | 8 | 16 | 85.7 | 14.3 | |
| Fluoroquinolones | Ciprofloxacin | ≤1 | 2 | ≥4 | 4 | 8 | 100.0 | 0.0 |
| Levofloxacin | ≤2 | 4 | ≥8 | 8 | 16 | 100.0 | 0.0 | |
| Tertracycline | Tertracycline | ≤4 | 8 | ≥16 | 8 | 16 | 95.2 | 4.8 |
| Trimethoprim/sulfamethoxazole | Trimethoprim/sulfamethoxazole | ≤2/38 | NA | ≥4/76 | NA | ≥4/76 | 100.0 | 0.0 |
| Fluoroquinolones | Colistin | ≤2 | NA | ≥4 | 0.5 | 1 | 0.0 | 100.0 |
| Polmyxin B | ≤2 | NA | ≥4 | 0.5 | 1 | 4.8 | 95.2 | |
| Glycylcyclin | Tigecycline | ≤2 | 4 | ≥8 | 0.5 | 1 | 0.0 | 100.0 |
| β-lactam/β -lactamase inhibitor combinations | Ampicillin/sulbactam | ≤8/4 | 16/8 | ≥32/16 | NA | ≥32/16 | 95.2 | 4.8 |
Fig. 2Gel picture for PCR used in this study.
Fig. 3Biofilm formation in microtiter plate.
Fig. 4Production of AHLs for study isolates.
PCR-based detection of virulence genes and QS producing abaI
| Sample/S.No | Biofilm | AHL production | Serum resitance | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | + | + | + | + | + | − | + | + |
| 2 | + | − | + | + | − | − | − | − |
| 3 | + | + | + | − | + | + | + | + |
| 4 | + | + | + | + | + | − | − | + |
| 5 | + | − | + | − | − | − | − | − |
| 6 | + | − | + | + | + | − | − | − |
| 7 | + | + | + | − | + | − | − | + |
| 8 | + | + | + | + | − | − | − | + |
| 9 | + | + | + | − | + | + | + | + |
| 10 | + | − | + | + | + | − | − | − |
| 11 | + | + | + | + | + | − | − | + |
| 12 | + | + | + | + | − | − | − | + |
| 13 | + | + | + | − | + | − | − | + |
| 14 | + | − | + | − | − | − | − | − |
| 15 | + | − | + | + | + | − | + | − |
| 16 | + | + | + | − | + | − | − | + |
| 17 | + | + | + | − | + | − | − | + |
| 18 | + | + | + | − | − | − | − | + |
| 19 | + | − | + | − | + | − | − | − |
| 20 | + | + | + | + | + | − | + | + |
| 21 | + | + | + | − | − | − | − | + |